Results 211 to 220 of about 162,486 (263)

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

open access: yesAdvanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia   +7 more
wiley   +1 more source

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial. [PDF]

open access: yesNat Commun
Sun Y   +64 more
europepmc   +1 more source

Current Treatment Patterns and Outcomes of Sex Cord Stromal Tumor Patients in Japan. [PDF]

open access: yesInt J Urol
Abe T   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy